Kythera Faces Advisory Committee Meeting For Double Chin Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The California biotech faces one last hurdle before potential approval of its double chin injectable ATX-101 when it comes in front of the FDA’s dermatology advisory committee.